Dexa-E Therapeutics

Dexa-E Therapeutics is a pre-clinical stage biotechnology company focused on developing targeted therapies for inflammatory diseases, with a primary emphasis on inflammatory bowel disease (IBD). The company's core technology involves a proprietary nanoparticle delivery system that utilizes E-selectin-targeted ligands to deliver dexamethasone specifically to inflamed vascular endothelium. By concentrating the therapeutic agent at the site of inflammation, Dexa-E aims to enhance efficacy while significantly reducing the systemic side effects typically associated with long-term corticosteroid use. Their lead program, Dexa-E, is being evaluated for the treatment of ulcerative colitis and Crohn's disease.